PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
-3.93%
Revenue decline while Healthcare median is -0.48%. Seth Klarman would investigate if market share loss is temporary.
13.44%
Cost increase while Healthcare shows cost reduction. Peter Lynch would examine competitive disadvantages.
-34.20%
Gross profit decline while Healthcare median is 0.00%. Seth Klarman would investigate competitive position.
-31.50%
Margin decline while Healthcare median is 0.00%. Seth Klarman would investigate competitive position.
-56.11%
R&D reduction while Healthcare median is -0.61%. Seth Klarman would investigate competitive implications.
-15.19%
G&A reduction while Healthcare median is 0.00%. Seth Klarman would investigate efficiency gains.
-8.63%
Marketing expense reduction while Healthcare median is 0.00%. Seth Klarman would investigate competitive implications.
73.61%
Other expenses change of 73.61% versus flat Healthcare costs. Walter Schloss would verify efficiency.
-9.49%
Operating expenses reduction while Healthcare median is -0.82%. Seth Klarman would investigate advantages.
3.70%
Total costs growth while Healthcare reduces costs. Peter Lynch would examine differences.
95.64%
Interest expense change of 95.64% versus flat Healthcare costs. Walter Schloss would verify control.
6.19%
D&A change of 6.19% versus flat Healthcare D&A. Walter Schloss would verify adequacy.
82.14%
EBITDA growth exceeding 1.5x Healthcare median of 5.14%. Joel Greenblatt would investigate advantages.
-14.41%
EBITDA margin decline while Healthcare median is 0.00%. Seth Klarman would investigate causes.
61.81%
Operating income growth exceeding 1.5x Healthcare median of 3.75%. Joel Greenblatt would investigate advantages.
60.25%
Margin change of 60.25% versus flat Healthcare. Walter Schloss would verify quality.
34.41%
Other expenses change of 34.41% versus flat Healthcare. Walter Schloss would verify control.
56.49%
Pre-tax income growth exceeding 1.5x Healthcare median of 7.01%. Joel Greenblatt would investigate advantages.
54.71%
Margin change of 54.71% versus flat Healthcare. Walter Schloss would verify quality.
-10.67%
Tax expense reduction while Healthcare median is 0.00%. Seth Klarman would investigate advantages.
53.38%
Net income growth exceeding 1.5x Healthcare median of 5.10%. Joel Greenblatt would investigate advantages.
51.47%
Margin change of 51.47% versus flat Healthcare. Walter Schloss would verify quality.
55.11%
EPS growth exceeding 1.5x Healthcare median of 9.26%. Joel Greenblatt would investigate advantages.
55.11%
Diluted EPS growth exceeding 1.5x Healthcare median of 9.09%. Joel Greenblatt would investigate advantages.
5.26%
Share count reduction below 50% of Healthcare median of 0.23%. Jim Chanos would check for issues.
5.26%
Diluted share reduction below 50% of Healthcare median of 0.29%. Jim Chanos would check for issues.